Table 2.
Correlation analysis of SFRP1 promoter methylation
| SFRP1 methylation | M (n = 18) | U (n = 27) | Total (n = 45) | p value |
|---|---|---|---|---|
| Gender | 0.021 | |||
| f | 5 (27.8%) | 17 (63.0%) | 22 (48.9%) | |
| m | 13 (72.2%) | 10 (37.0%) | 23 (51.1%) | |
| Age at diagnosis in month | < 0.001 | |||
| nd | 1 | 0 | 1 | |
| Mean (SD) | 98.48 (73.09) | 31.50 (37.82) | 57.38 (62.78) | |
| Range | 7.37–199.44 | 0.00–156.33 | 0.00–199.44 | |
| Outcome | 0.287 | |||
| DOD | 5 (27.8%) | 4 (14.8%) | 9 (20.0%) | |
| NED | 13 (72.2%) | 23 (85.2%) | 36 (80.0%) | |
| Cause of death | 0.512 | |||
| nd | 1 | 0 | 1 | |
| Progressive | 2 (11.8%) | 2 (7.4%) | 4 (9.1%) | |
| Recurrence | 3 (16.6%) | 2 (7.4%) | 5 (11.1%) | |
| Alive | 12 (70.6%) | 23 (85.2%) | 35 (79.5%) | |
| Tumor type | 0.004 | |||
| HB | 7 (38.9%) | 23 (85.2%) | 30 (66.7%) | |
| HCC/TLCT | 10 (55.6%) | 3 (11.1%) | 13 (28.9%) | |
| NSET | 1 (5.6%) | 1 (3.7%) | 2 (4.4%) | |
| Differentiation | 0.042 | |||
| nd | 1 | 1 | 2 | |
| Epithelial | 8 (47.1%) | 15 (57.7%) | 23 (53.5%) | |
| Fibrolamellar | 4 (23.5%) | 0 (0.0%) | 4 (9.3%) | |
| Well differentiated | 1 (5.9%) | 1 (3.8%) | 2 (4.4%) | |
| Moderately differentiated | 2 (11.8%) | 1 (3.8%) | 3 (7.0%) | |
| Mixed | 2 (11.8%) | 9 (34.6%) | 11 (25.6%) | |
| Component | 0.260 | |||
| na | 8 (44.4%) | 3 (11.1%) | 11 (24.4%) | |
| E | 0 (0.0%) | 1 (3.7%) | 1 (2.2%) | |
| E/F | 3 (16.7%) | 6 (22.2%) | 9 (20.0%) | |
| E > F | 1 (5.6%) | 1 (3.7%) | 2 (4.4%) | |
| F | 2 (11.1%) | 4 (14.8%) | 6 (13.3%) | |
| F > E | 4 (22.2%) | 11 (40.7%) | 15 (33.3%) | |
| pure OS | 0 (0.0%) | 1 (3.7%) | 1 (2.2%) | |
| Stage | 0.078 | |||
| nd | 1 | 2 | 3 | |
| I | 5 (29.4%) | 2 (8.0%) | 7 (16.7%) | |
| II | 1 (5.9%) | 0 (0.0%) | 1 (2.4%) | |
| III | 4 (23.5%) | 14 (56.0%) | 18 (42.9%) | |
| IV | 7 (41.2%) | 9 (36.0%) | 16 (38.1%) | |
| PRETEXT | 0.552 | |||
| nd | 4 | 0 | 4 | |
| 1 | 1 (6.7%) | 1 (3.7%) | 2 (4.8%) | |
| 2 | 6 (40.0%) | 8 (29.6%) | 14 (33.3%) | |
| 3 | 5 (33.3%) | 14 (51.9%) | 19 (45.2%) | |
| 4 | 2 (13.3%) | 4 (14.8%) | 6 (14.3%) | |
| Extrahepatic | 0.020 | |||
| nd | 2 | 0 | 2 | |
| No | 13 (81.2%) | 27 (100.0%) | 40 (93.0%) | |
| Yes | 3 (18.8%) | 0 (0.0%) | 3 (7.0%) | |
| Multifocal | 0.280 | |||
| nd | 3 | 0 | 3 | |
| No | 10 (66.7%) | 22 (81.5%) | 32 (76.2%) | |
| Yes | 5 (33.3%) | 5 (18.5%) | 10 (23.8%) | |
| Metastasis | 0.598 | |||
| nd | 1 | 0 | 1 | |
| No | 10 (58.8%) | 18 (66.7%) | 28 (63.6%) | |
| Yes | 7 (41.2%) | 9 (33.3%) | 16 (36.4%) | |
| Chemotherapy | 0.761 | |||
| No | 4 (22.2%) | 5 (18.5%) | 9 (20.0%) | |
| Yes | 14 (77.8%) | 22 (81.5%) | 36 (80.0%) | |
| Resection margin | 0.046 | |||
| nd | 3 | 0 | 3 | |
| R0 | 11 (64.7%) | 25 (92.6%) | 36 (81.8%) | |
| R1 | 4 (23.5%) | 2 (7.4%) | 6 (13.6%) | |
| 16-gene signature | 0.871 | |||
| na | 1 (5.6%) | 1 (3.7%) | 2 (4.4%) | |
| C1 | 10 (55.6%) | 17 (63.0%) | 27 (60.0%) | |
| C2 | 7 (38.9%) | 9 (33.3%) | 16 (35.6%) | |
| CTNNB1 | 0.340 | |||
| Mutant | 16 (88.9%) | 21 (77.8%) | 37 (82.2%) | |
| Wildtype | 2 (11.1%) | 6 (22.2%) | 8 (17.8%) | |
| NFE2L2 | 0.571 | |||
| nd | 2 | 1 | 3 | |
| Mutant | 1 (6.2%) | 3 (11.5%) | 4 (9.5%) | |
| Wildtype | 15 (93.8%) | 23 (88.5%) | 38 (90.5%) | |
| TERT | 0.008 | |||
| nd | 1 | 0 | 1 | |
| Mutant | 4 (23.5%) | 0 (0.0%) | 4 (9.1%) | |
| Wildtype | 13 (76.5%) | 27 (100.0%) | 40 (90.9%) | |
| SFRP1 expression | 0.908 | |||
| Mean (SD) | 1.327 (1.956) | 1.265 (1.575) | 1.290 (1.716) | |
| Range | 0.015–6.287 | 0.029–6.450 | 0.015–6.450 | |
| SFRP1 exp. category | 0.616 | |||
| High | 6 (33.3%) | 11 (40.7%) | 17 (37.8%) | |
| Low | 12 (66.7%) | 16 (59.3%) | 28 (62.2%) | |
Chi-square correlation analysis of methylated (M) and unmethylated (U) SFRP1 categories to different clinicopathological and experimental parameters
m male, f female, DOD died of disease, NED no evidence of disease, HB hepatoblastoma, HCC hepatocellular carcinoma, TLCT transitional liver cell tumor, NSET nested stromal-epithelial liver tumor, E embryonal, F fetal, pure OS pure osteoid, C1 and C2 16-gene signature cluster C1 and C2 (Cairo et al. 2008), nd no data, na not applicable